Can Indivior Pharmaceuticals, Inc. cover its short-term obligations?

Its current ratio is 0.86 — current liabilities exceed current assets.

Where does Indivior Pharmaceuticals, Inc. 's balance sheet data come from?

Every line is extracted from Indivior Pharmaceuticals, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Indivior Pharmaceuticals, Inc. INDV Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$175M-53.0%	$195M-38.9%	$445M+54.5%	$510M—	$372M—
Accounts receivable, net	$1.03B+106%	$995M+296%	$996M+297%	$728M+171%	$498M+86.9%
Inventories	$21M-41.7%	$32M-37.3%	$40M-76.0%	$45M-72.3%	$36M-76.9%
Work in process	$59M—	$49M—	$43M—	——	——
Finished goods	$69M—	$75M—	$82M—	——	——
Prepaid expenses and other current assets	$15M—	$34M—	$30M—	——	——
Income taxes receivable	$12M—	$2M—	$13M—	——	——
Total current assets	$667M—	$652M—	$922M—	——	——
Property and equipment, net	$157M—	$144M—	$124M—	——	——
Accumulated depreciation	$111M—	$107M—	$106M—	——	——
Operating lease right-of-use assets	$22M—	$26M—	$30M—	——	——
Goodwill	$2M—	$2M—	$2M—	——	——
Deferred tax assets	$1.17B+124%	$1.16B+368%	$1.11B+334%	$820M+233%	$523M+104%
Other non-current assets	$26M—	$27M—	$27M—	——	——
Equity method investments	$27M—	$28M—	$28M—	——	——
Total assets	$1.2B—	$1.2B—	$1.42B—	——	——
Accounts payable	$35M—	$48M—	$41M—	——	——
Accrued expenses	$42M—	$103M—	$79M—	——	——
Current portion of long-term debt	$0—	$29M—	$18M—	——	——
Operating lease liabilities, current	$9M—	$10M—	$10M—	——	——
Income taxes payable	$26M—	$2M—	$4M—	——	——
Total current liabilities	$779M—	$914M—	$965M—	——	——
Long-term debt	$486M—	$290M—	$304M—	——	——
Operating lease liabilities, non-current	$14M—	$22M—	$24M—	——	——
Operating Lease Liabilities (Total)	——	——	——	——	——
Other non-current liabilities	$21M—	$21M—	$30M—	——	——
Total liabilities	$1.34B—	$1.3B—	$1.62B—	——	——
Common stock	$0—	$62M—	$62M—	——	——
Additional paid-in capital	$165M—	$112M—	$109M—	——	——
Retained earnings	-$280M—	-$243M—	-$346M—	——	——
Accumulated other comprehensive income (loss)	-$29M—	-$30M—	-$32M—	——	——
Total stockholders' equity	-$144M+49.5%	-$98M+70.9%	-$207M+33.2%	-$257M—	-$285M—
Total liabilities and stockholders' equity	$1.2B—	$1.2B—	$1.42B—	——	——
Allowance for Doubtful Accounts	$3M—	$4M—	$2M—	——	——
Allowance for Doubtful Accounts Receivable (Current)	$3M—	$4M—	$2M—	——	——
Finished goods	$69M—	$75M—	$82M—	——	——
Other current assets	$40M—	$16M—	$19M—	——	——
Deferred Tax Assets and Other Non-Current Assets	$26M—	$27M—	$27M—	——	——
Goodwill and Intangible Assets, Net	$2M—	$2M—	$2M—	——	——
Net Investment in Lease	$22M—	$26M—	$30M—	——	——
Deferred tax assets	$296M—	$323M—	$285M—	——	——
Goodwill and intangible assets, net	$2M—	$2M—	$2M—	——	——
Investments	$27M—	$28M—	$28M—	——	——
Operating lease right-of-use assets	$22M—	$26M—	$30M—	——	——
Other non-current assets	$26M—	$27M—	$27M—	——	——
Property, plant and equipment at cost	$268M—	$251M—	$230M—	——	——
Operating Lease Right-of-Use Assets in Other Assets	$22M—	$26M—	$30M—	——	——
Software and Technology Licenses, Net	$26M—	$27M—	$27M—	——	——
Accrued Litigation	$41M—	$52M—	$300M—	——	——
Accrued Manufacturing Costs	$42M—	$103M—	$79M—	——	——
Accrued Rebates, Returns, and Promotions	$551M—	$582M—	$613M—	——	——
Accounts payable and other current liabilities (Note 11)	$178M—	$250M—	$215M—	——	——
Accrued Income Taxes, Current	$26M—	$2M—	$4M—	——	——
Compensation and benefits	$42M—	$103M—	$79M—	——	——
Professional Service Fees Payable	$92M—	——	——	——	——
Accrued litigation	$14M—	$42M—	$106M—	——	——
Total debt	$509M—	$351M—	$356M—	——	——
Unrecognized Tax Benefits	$5M—	——	——	——	——
Common Stock Par Value Per Share	$0.00—	$0.50—	$0.50—	——	——
Common Stock Shares Issued	122M—	125M—	125M—	——	——
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$0—	$62M—	$62M—	——	——
Share Price	——	——	——	——	——
Cumulative Cost Basis	$268M—	$251M—	$230M—	——	——
Professional service fees	$92M—	——	——	——	——
Allowance for doubtful accounts	$3M—	$4M—	$2M—	——	——
Common stock, exchange ratio	——	——	——	——	——
Common stock, par value (in dollars per share)	$0—	$0.5—	$0.5—	——	——
Common stock, shares issued (in shares)	$122M—	$125M—	$125M—	——	——
Customer refunds and credits	$551M—	$582M—	$613M—	——	——
Tax receivable within other current assets	$12M—	$2M—	$13M—	——	——
Raw materials and consumables	$26M—	$31M—	$32M—	——	——
Estimated litigation liability	$55M—	$94M—	$406M—	——	——
Estimated Litigation Liability, Noncurrent	$41M—	$52M—	$300M—	——	——
Other accrued liabilities	$4M—	$3M—	$8M—	——	——
Prepaid expenses	$15M—	$34M—	$30M—	——	——
Share price (in dollars per share)	——	——	——	——	——
Total Inventories, Net, Current And Noncurrent	$154M—	$154M—	$157M—	——	——
Unrecognized tax benefits	$5M—	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can Indivior Pharmaceuticals, Inc. cover its short-term obligations?: Its current ratio is 0.86 — current liabilities exceed current assets.
Where does Indivior Pharmaceuticals, Inc. 's balance sheet data come from?: Every line is extracted from Indivior Pharmaceuticals, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.